BARIANI, Maria Carolina Prado Fleury et al. Mycosis fungoides and Kaposis sarcoma association in an HIV-negative patient. An. Bras. Dermatol. [online]. 2016, vol.91, n.5, suppl.1, pp.108-110. ISSN 0365-0596. http://dx.doi.org/10.1590/abd1806-4841.20164401.. The association of mycosis fungoides and kaposis sarcoma in HIV-negative patients is a rare phenomenon. The presence of human herpesvirus 8 (HHV-8) - associated with all forms of Kaposis sarcoma - has also been recently identified in mycosis fungoides lesions. However, a causal association between HHV-8 and the onset of mycosis fungoides has not been established yet. The present case reports a patient who developed Kaposis sarcoma lesions after a two-year UVB phototherapy to treat a mycosis fungoides. Negative immunohistochemistry staining for Kaposis sarcoma-associated herpesvirus in the initial mycosis fungoides lesions strengthens the absence of a link between Kaposis sarcoma-associated herpesvirus and mycosis fungoides. ...
Purpose: To determine the effect of low-dose (4 Gy) total skin electron beam therapy as a second-line treatment of Stage IB-II mycosis fungoides in a prospective, open-label study. Methods and Materials: Ten patients (6 men, 4 women, average age 68.7 years [range, 55-82 years]) with histopathologically confirmed mycosis fungoides T2-T4 N0-N1 M0 who did not achieve complete remission or relapsed within 4 months after treatment with psoralen plus ultraviolet-A were included. Treatment consisted of low-dose total skin electron beam therapy administered at a total skin dose of 4 Gy given in 4 fractions over 4 successive days. Results: Two patients had a complete clinical response but relapsed after 3.5 months. Six patients had partial clinical responses, with a mean duration of 2.0 months. One patient had no clinical response. Median time to relapse was 2.7 months. One patient died of unrelated causes and did not complete treatment. Acute side effects included desquamation, xerosis, and erythema of ...
Sézary syndrome (SS) and Mycosis Fungoides (MF) are T-cell lymphomas whose primary manifestation is in the skin. Mycosis Fungoides, is the most common form of cutaneous T-cell lymphoma. It generally affects the skin, but may progress internally over time.The name mycosis fungoides is somewhat misleading--it loosely means "mushroom-like fungal disease". The disease, however, is not fungal infection but rather a type of non-Hodgkins lymphoma. It was so named because the skin tumors of a severe case as having a mushroom-like appearance.. Sézarys disease (or "Sézary syndrome") is a type of cutaneous lymphoma characterized by Albert Sézary."Sézarys cells" are T-cells that have pathological quantities of mucopolysaccharides. Sézarys disease is sometimes considered a late stage of mycosis fungoides. Click here for instructions on how to download the free FCS Express Reader to view and manipulate the sample cases.. ...
Results: Among 254 MF patients, 25 patients with T-MF are identified (10.2%) and included in the study. Male to female ratio was 2.6/1. The median time between MF diagnosisand transformation was 32 months (range 0-192). Nine (36%) patients were diagnosed initially with T-MF. Advanced disease stage and high serum lactate dehydrogenase levels were indicators of poor prognosis and treatment response. Five of the 18 patients with progressive disease had undergone allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Allo-HSCT resulted in complete remission in three (60%) patients. Ten (40%) patients died as a result of disease progression. Mean survival time was 25,2 14,9 (2-56) months after transformation ...
Dendritic cells (DCs) are antigen-presenting cells with an important role in the innate and adaptive immune system. In skin lesions, cutaneous DCs (Langerhans cells, dermal DCs and plasmacytoid DCs) are involved in immune activation in inflammatory benign lesions, as well as in malignant lymphoid proliferations. Density and distribution of DCs in the dermal infiltrate can be helpful to differentiate benign, reactive infiltrate from malignant nature of the lymphoid population. We performed a retrospective study including 149 patients: 35 with mycosis fungoides, 35 with spongiotic dermatitis, 35 with psoriasis, 35 with lupus and 9 with cutaneous T-cell lymphomas (other than mycosis fungoides), diagnosed using histopathological and immunohistochemical stains. Density and distribution of DCs were evaluated using specific markers (CD1a, CD11c and langerin). In all cases, numerous DCs were identified in the dermal infiltrate. Their number was significantly increased in mycosis fungoides and T-cell ...
TY - JOUR. T1 - Sézary syndrome and mycosis fungoides. T2 - An overview, including the role of immunophenotyping. AU - Pulitzer, Melissa P.. AU - Horna, Pedro. AU - Almeida, Julia. PY - 2020/1/1. Y1 - 2020/1/1. N2 - This review discusses the definition and major categories of cutaneous T-cell lymphoma, Sézary syndrome and mycosis fungoides, and the role of immunophenotyping in their diagnosis. The following key points are raised: (a) Sézary syndrome and mycosis fungoides cells most often have a characteristic CD3+ CD4+ CD7− and/or CD26− immunophenotype. (b) This immunophenotype is not specific, but can assist in the distinction from non-neoplastic T cells and other subtypes of mature T-cell neoplasm. (c) However, small subsets of normal and reactive T-cells can have an overlapping immunophenotype, and can be distinguished by evaluating for additional changes in antigen expression.. AB - This review discusses the definition and major categories of cutaneous T-cell lymphoma, Sézary ...
TY - JOUR. T1 - Mycosis fungoides and Sézary syndrome. T2 - Clinical, immunological and molecular distinctions that suggest two different diseases. AU - Wu, Xuesong. AU - Hwang, Samuel T. PY - 2012/4. Y1 - 2012/4. N2 - Although mycosis fungoides and Sézary syndrome are presently defined by the WHO/European Organization for Research and Treatment of Cancer criteria as two distinct subtypes of cutaneous T-cell lymphoma, the two diseases present with some overlapping clinical and pathological features and share the same staging system. Advances in understanding the roles and immunologic features of different subsets of T helper cells have allowed researchers to segregate mycosis fungoides and Sézary syndrome with more precision, suggesting that these diseases, despite some similarities, arise from distinct T-cell subsets. New evidence acquired from recent studies in genetics and molecular signaling pathways has contributed to a more comprehensive understanding of these two disease entities, ...
17 NCCN Guidelines for Patients ® Mycosis Fungoides, Version 1.2016 2 Treatment planning Physical exam Physical exam Doctors should perform a physical exam along with taking a medical history. A physical exam is a study of your body for signs of disease. During this exam, your doctor will listen to your lungs, heart, and gut. Parts of your body will likely be felt to see if organs are of normal size, are soft or hard, or cause pain when touched. For mycosis fungoides, a skin exam of your total body is needed. While mycosis fungoides is often confined to the torso, this exam includes areas like your scalp, between your legs, and toe webs. Your doctor will note the type of skin lesions and assess how much of your skin has lesions. He or she will also assess if any lymph nodes or other organs are enlarged. Chart 2.1 Care before treatment Must haves Sometimes useful • Medical history • Neck CT • Physical exam with total body skin exam • Bone marrow biopsy • Complete blood count • Biopsy ...
Mycosis Fungoides is a rare type of skin lymphoma (tumors of the blood). This site will describe about mycosis fungoides, causes of mycosis fungoides and treatment, possible symptoms and its related complications includes itching, tumors and patches.
Do You Have Mycosis Fungoides, Familial? Join friendly people sharing true stories in the I Have Mycosis Fungoides, Familial group. Find support forums, advice and chat with groups who share this life experience. A Mycosis Fungoides, Familial anonymo...
Extracutaneous manifestations of mycosis fungoides imply a bad prognosis and are a major cause of death. Benign dermatopathic lymphadenopathy is associated with mycosis fungoides and often precedes lymphomatous infiltration. In this study, 10 patient
For staging, bone marrow biopsy and CT of chest, abdomen, and pelvis.. PET scan may also be used for suspected visceral involvement.. Treatment:. Mycosis Fungoides is treated with topical steroids, ultraviolet light and psoralens, electron beam radiation therapy or topical nitrogen mustard. Electron beam radiation therapy, in which most of the energy is absorbed in the first 5 to 10 mm of tissue, and topical nitrogen mustard have proved highly effective. Systemic treatment is primarily used when other therapies have failed, after relapse, or in patients with documented extranodal or extracutaneous disease. Systemic therapy is also given for Sezary Cell Leukemia. Various lymphoma-type regimens are used.. Prognosis:. Median survival in Mycosis Fungoides is 7 to 10 years after diagnosis. However, survival rates vary markedly depending on the stage at diagnosis.. The prognosis is worse in Sezary Cell Leukemia.. References:. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous ...
TY - JOUR. T1 - Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. AU - Vacca, A.. AU - Moretti, S.. AU - Ribatti, D.. AU - Pellegrino, A.. AU - Pimpinelli, N.. AU - Bianchi, B.. AU - Bonifazi, E.. AU - Ria, R.. AU - Serio, G.. AU - Dammacco, F.. PY - 1997/9. Y1 - 1997/9. N2 - Changes in angiogenesis and expression of extracellular matrix-degrading enzymes have been substantiated during progression of solid tumours, whereas information on haematological tumours remains circumstantial. In this study, 57 biopsies of mycosis fungoides (MF), a haematological tumour of T-cell lineage, were investigated immunohistochemically for the extent of angiogenesis, and by in situ hybridisation for the expression of matrix metalloproteinases 2 (MMP-2, collagenase A) and 9 (MMP-9, collagenase B). The biopsies we grouped according to the stage of progression: patch → plaque → nodular (most advanced). The extent of angiogenesis, ...
None! Mycosis fungoides is the common name for the most common type of cutaneous T-cell lymphoma. A lymphoma is a malignancy of the white blood cells that are known as lymphocytes. Mycosis fungoides primary involves the skin and produces patches, plaques and tumors. The patches may be scaly or flaky and can thus look a lot like an ordinary rash such as the rash of proriasis or of a non-specific dermatitis. Many times, the plaque-like rash will look like a fungal dermatitis, and thus the name for the syndrome. However, there really is not a fungus involved.. ...
It was the purpose of this study to characterize the proliferating cells in skin lesion of Sézarys syndrome and of mycosis fungoides by means of their surface markers and their response to Phytohemagglutinine mitogen stimulation. Viable infiltrating cells were freed from skin biopsy specimens by means of a disaggregating homogenizer and the cells yielded were tested with heterologius polyvalent anti-human Ig and with anti-human T-cell globulin, as well as for spontaneous rosette formation with sheep red blood cells (SRBC) and for their response to stimulation with Phytohemagglutinine. Most of the infiltrating cells in skin lesions of mycosis fungoides and Sézarys syndrome lack receptors for anti-human Ig but form spontaneous rosettes with SRBC and have receptors for anti-T-cell globulin, indicating the T-lymphocyte nature of the infiltrating cells; however, their response to Phytohemagglutinine is weak. The results indicate the atypical, presumably neoplastic, nature of T-lymphocytes proliferating
TY - JOUR. T1 - Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. AU - Huang, Amy H.. AU - Kwatra, Shawn G.. AU - Khanna, Raveena. AU - Semenov, Yevgeniy R.. AU - Okoye, Ginette A.. AU - Sweren, Ronald J.. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Objective: Racial and gender disparities in mycosis fungoides (MF) are understudied. The objective of this study was to test the hypothesis that worse prognosis in blacks with MF is mediated by higher disease stage at diagnosis and by earlier disease onset in black females. Methods: We conducted retrospective chart review of 337 patients with clinically-suspected MF seen at Johns Hopkins between 2003 and 2018, requiring biopsy-proven disease for study inclusion. Patient demographics, initial stage/percent body surface area (BSA) involvement, pathology type, flow cytometry results, and treatment regimens were recorded. Results: Of 303 patients with confirmed MF, 166 (55%) were white, 107 (35%) black, 10 (3.3%) ...
First, lets define what mycosis fungoides is. It is a type of blood cancer. What it does is it affects the skin of the person primarily, and then over time, it will slowly progress internally. Common symptoms include but not limited to itchy skin, skin lesions, tumors, and rash.. The cause of this type of cancer until now is still unclear. Most of the case, it is not hereditary also it usually affects people who are at the age of 20 and more. Men are the ones who get this more compared to women. Various treatments include ultraviolet light, exposure to the sunlight, chemotherapy, topical corticosteroids, as well as radiotherapy.. Lets discuss in detail about its symptoms that are visible. One thing is for sure; it does affect the skin. So, there will be lesions, rashes, tumors, and even itching is also common. The symptoms do not appear right away. They do pop up progressively. Thus, expect during the early stages of mycosis fungoides, there will be the appearance of lesions of which will be ...
The ICD-10 Code C84.05 is the code used for Mycosis fungoides, nodes of inguinal region and lower limb .An alternative description for this code is Mycosis fungoides, lymph nodes of inguinal region ...
AbstractTHIRTEEN patients with mycosis fungoides have been seen at the Cleveland Clinic. Nine were men and 4 women. The youngest patient to develop the disease in this series was a 22-year-old woman and the oldest a woman aged 71.Twelve of the patients were white and 1 was colored. Occupation was not significant. The duration of the disease before being seen at the Clinic varied from 1 month to 10 years.One patient developed dermatitis venenata which was followed by a generalized exfoliative dermatitis on which lesions of mycosis fungoides developed 4 years later. Another patient had
Background: Peripheral blood involvement is recognised as an adverse prognostic factor in Mycosis Fungoides (MF) & Sézary Syndrome (SS) which is reflected in the revised staging for MF/SS using blood (B) classification. Various methods exist to assess B classification.Objective: To assess peripheral blood involvement in MF/SS using T-cell receptor (TCR) analysis, lactate dehydrogenase levels and flow cytometric immunophenotyping. Methods: 57 consecutive patients with MF/SS assessed at our Cutaneous Lymphoma Centre, University Hospital Birmingham, UK between 2011 and 2014 were identified: 30 with early stage (I-IIA) and 27 with advanced disease (IIB-IV).Results: In early stage disease, 2/30 (7%) had identical TCR clones in skin and blood compared to 14/27 (52%) in advanced disease (p | 0.001). Abnormal immunophenotyping was found in 7/27 patients (26%) with advanced disease (p = 0.003) which included 6/14 (43%) erythrodermic patients but none in early stage disease. Elevated LDH was the most frequent
SUMMARY Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of malignant lymphomas that share the propensity for malignant T lymphocytes expressing cutaneous lymphocyte antigen to infiltrate the skin. Mycosis fungoides (MF) is the most common variant of CTCL, representing approximately 50 percent of all cases. Sézary syndrome (SS) is a leukemic variant of MF, affecting approximately 5 percent of patients with MF.1 MF and SS are the most common malignant proliferations of mature memory T lymphocytes of the helper phenotype (CD4+CD45RO+),2 which renders patients immunocompromised even at the earliest stages of the disease. Advanced stages are associated with severe immune suppression. Diagnosis is established by skin biopsy, followed by staging work up which includes radiologic imaging and pathologic evaluation of the lymph nodes, internal organs, blood, and marrow, as appropriate, according to presenting manifestations of the disease.. MF is divided into early and advanced stages for ...
Klemke, C D; Booken, N; Weiss, C; Nicolay, J P; Goerdt, S; Felcht, M; Géraud, C; Kempf, W; Assaf, C; Ortonne, N; Battistella, M; Bagot, M; Knobler, R; Quaglino, P; Arheiliger, B; Santucci, M; Jansen, P; Vermeer, M H; Willemze, R (2015). Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. British Journal of Dermatology, 173(1):93-105.. Whittaker, S; Ortiz, P; Dummer, R; Ranki, A; Hasan, B; Meulemans, B; Gellrich, S; Knobler, R; Stadler, R; Karrasch, M (2012). Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). British Journal of Dermatology, 167(3):678-687.. Olsen, E A; Whittaker, S ...
Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model Academic Article ...
The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.
Mycosis fungoides is a malignant lymphoma characterized by the expansion of a clone of CD4+ (or helper) memory T cells (CD45RO+) that normally patrol and home in on the skin.{ref5} The malignant clone... more
Adult patients with mycosis fungoides (MF) have a higher risk of secondary malignancies, according to a 20-year population-based cohort study. The researchers, from Bezmialem Vakif University in Istanbul, Turkey, say their findings support earlier research about a higher risk of, for instance, Hodgkin lymphoma, chronic leukemia, and lung cancer.. Between 1998 and 2015, the researchers documented 143 cases of cutaneous T-cell lymphoma (CTCL). The majority of patients had early-stage disease.. [embed:render:related:node:112541]. The researchers also documented 13 cases (9%) of secondary malignancy diagnosed at least 3 months after the diagnosis of CTCL. The cancers included bladder cancer, nasopharynx cancer, renal cell carcinoma, lung cancer, and superficial spreading malignant melanoma.. Older age, stage IV disease, lymphomatoid papulosis, and having CTCL for , 10 years raised the chances of developing secondary solid tumors. In 60% of patients, the secondary malignancies occurred during the ...
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T cell lymphoma (CTCL).MF is a mature T cell non-Hodgkin lymphoma with presentation in the skin but with potential involvement of the nodes, blood, and viscera.
MRG-106, an RNA-based therapy, induced clinical improvements in 90 percent of patients with mycosis fungoides - a subtype of cutaneous T-cell lymphoma (CTCL) - in a Phase 1 trial.
64 NCCN Guidelines for Patients ® Mycosis Fungoides, Version 1.2016 1.1 H1 Here Body text here. 3 DCIS Genetic counseling , Treatment 4 Treatment guide Website , Review Websites American Cancer Society cancer.org/cancer/non-hodgkinlymphoma/ detailedguide/index National Coalition for Cancer Survivorship www.canceradvocacy.org/toolbox National Cancer Institute cancer.gov/types/lymphoma NCCN nccn.org/patients The Leukemia & Lymphoma Society (LLS) LLS.org/informationspecialists Review • Shared decision-making is a process in which you and your doctors plan treatment together. • Asking your doctors questions is vital to getting the information you need to make informed decisions. • Getting a 2 nd opinion, attending support groups, and comparing benefits and downsides may help you decide which treatment is best for you. ...
Tokyo, Japan 26th November, 2018 - Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a humanised monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4), for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Mycosis fungoides and Sézary syndrome are diseases in which lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin.
TY - JOUR. T1 - Mycosis fungoides with testicular involvement. T2 - A rare phenomenon. AU - Khawaja, Muhammad Rizwan. AU - Mark, Lawrence. AU - Alexander, Riley E.. AU - Nassiri, Mehdi. AU - Azar, Jose. PY - 2012/7. Y1 - 2012/7. UR - http://www.scopus.com/inward/record.url?scp=84862316848&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84862316848&partnerID=8YFLogxK. U2 - 10.1016/j.leukres.2012.03.009. DO - 10.1016/j.leukres.2012.03.009. M3 - Article. C2 - 22560335. AN - SCOPUS:84862316848. VL - 36. JO - Leukemia Research. JF - Leukemia Research. SN - 0145-2126. IS - 7. ER - ...
Mycosis fungoides associated with unusual epidermal hyperplasia.: A 58-year-old white woman presented with widespread pruritic brownish plaques and hyperpigment
OUTLINE: Patients are stratified by disease (Sezary syndrome vs mycosis fungoides) and prior treatment (yes vs no).. All patients receive a physical examination, and a medical history is taken. Patients with Sezary syndrome undergo leukapheresis. Patients with plaque/tumor stage mycosis fungoides undergo skin biopsy of involved skin. Malignant T cells from blood or skin are then isolated and patterns of gene expression in the malignant T cells are compared to those in normal skin-homing T cells from healthy donors using a gene chip (Lymphochip).. Patients are followed annually for 5 years.. PROJECTED ACCRUAL: A total of 40 patients (20 per disease stratum) will be accrued for this study within 2 years. ...
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject-specific sections.
A 48-year-old man was referred to our institution for acute limb ischaemia. He had been diagnosed with cutaneous T-cell lymphoma, so-called mycosis fungoides by gene rearrangement analysis of skin biopsy samples 9 years ago. He had received prednisolone 5 mg daily and phototherapy for mycosis fungoides. Although allergy symptoms and signs including asthma, peripheral neuropathy and glomerulonephritis had not been evident, his rashes had been worsening in his face and abdomen for a few months.. On examination, enhanced CT revealed thrombotic occlusion in the left posterior tibial artery (figure 1A, B) and multiple aneurysms of various systemic peripheral vascular beds, including those of posterior tibial artery, ulnar artery and so on. Laboratory test showed slight elevation of C reactive protein (0.40 mg/dL) and hypereosinophilia (leucocyte count 5.5×109/L, eosinophil 19.4%), whereas antineutrophil cytoplasmic antibody (ANCA) was negative. Cardiac MRI showed late gadolinium enhancement in ...
An actual publication by Lindahl et al. reviewed 35 patients with CTCL treated with TSEBT in Denmark between 2001 and 2008. Almost all patients had previous treatments and 40% of patients had T2 disease. The median follow-up time was 7.6 months and 25 patients were treated with high-dose (30 Gy) TSEBT and 10 patients in a low-dose (4 Gy) protocol. The group of patients with low-dose TSEBT had inadequate treatment response (CR in 10%) compared to higher-doses (26-30 Gy in 1 Gy fractions; CR in 68%). Overall, 28% showed progressive disease, 22.2% in T2 and 35.7% in T3 stage. Median time to progression was 9 months. Side effects related to TSEBT were documented in 88% of patients, including erythema and ulceration in 80%. The most common long-term side effect was alopecia (44%), dry skin (36%), hyperpigmentation (28%), ocular irritation (24%) and temporary loss of finger nails (16%). Furthermore, 2 patients developed basal cell carcinoma and one patient a squamous cell carcinoma. However, in 1 of ...
Galper et al. should be commended for their concise and useful review of the diagnosis and management of mycosis fungoides (MF). It is notable that all of the authors are radiation oncologists. While the reader may expect a radiation oncologists perspective on the management of mycosis fungoides, their review goes beyond highlighting the various radiation techniques used in the treatment of MF. It highlights the major diagnostic dilemmas when evaluating patients with skin lesions that eventually are diagnosed as MF or its leukemic counterpart, Sézary syndrome (SS). It also stresses the importance of a multidisciplinary approach in diagnosing and caring for MF patients involving dermatology, dermatopathology, radiation oncology, and hematology/oncology, and provides a concise review of the treatment options in the MF and SS armamentarium. Navigating these options requires a good understanding of the natural history of the disease, the side effects of treatment, the expected response rates of ...
Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800-638-3030 (within USA), 301-223-2300 (international) [email protected] ...
Sézary syndrome is very rare, making up ,5% of cutaneous T cell lymphomas (therefore at least 10 times less common than mycosis fungoides). It has a similar age of onset and no known aetiology. It can be considered a leukaemic version of mycosis fungoides.. ...
UV- based (PUVA and Narrow Band UVB) phototherapy is broadly and commonly used in the treatment of Cutaneous T-cell Lymphomas (CTCL), yet unfortunately the evidence for the efficacy of these treatments is based only on cases series or prospective but non-randomized studies. Therefore, no internationally approved guidelines exists and no standardization of schedules have been proposed. Recently, Consensus guidelines have been published by the United States Cutaneous Lymphoma Consortium. The aim of this paper is to review the biologic and clinical evidences on PUVA and NB UVB in CTCL, and to critically evaluate acceptability and feasibility of these guidelines in the real-life setting from the perspective of the Cutaneous Lymphoma Task Force of the Italian Lymphoma Foundation (Fondazione Italiana Linfomi, FIL ...
Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkins lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or ...
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLMs limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information ...
Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4+/CLA+/CCR4+ T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.. ...
Over a period of time, lymphocytes may lose their predilection for the epidermis, and may target the dermis, lymph nodes and other organs, converting MF into a more aggressive and resistant leukemia. At times, MF can undergo large cell transformation (anaplastic cells or immunoblasts) associated with a worse prognosis.. Romedepsis and vorinostat are potent inhibitors of the CYP enzyme system and can lead to serious toxicities of medications which are metabolized by similar CYP enzymes.. Treatment with systemic retinoids are associated with hypertriglyceridemia, hypercholesterolemia, thyroid and liver abnormalities, requiring replacement of thyroid hormone and lipid-lowering treatment during management.. Ultra-potent glucocorticoids should not be used on the face and neck as these areas are susceptible to steroid-induced complications. Also, use of steroids for prolonged periods of time is associated with skin breakdown and cutaneous infections.. Nitrogen mustard is commonly associated with ...
Key Points. A validated 3-miRNA classifier can effectively predict progression from early- to advanced-stage MF and survival at time of diagnosis.This classifi
Diagnosis Code C84.02 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Diagnosis Code C84.04 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Mit klonspezifischer Polymerasekettenreaktion (PCR) ist ein spezifischer Nachweis kleiner DNA-Mengen möglich. Von 47 MF-Patienten wurden aus Hautproben 50 TCR-gamma- und 7 TCR-beta-Sequenzen sequenziert, von 15 bzw. 5 Patienten gelang die Entwicklung eines N-spezifischen Primers. Um einen Zusammenhang zwischen Frequenz der zirkulierenden klonalen Zellen und klinischem Verlauf zu untersuchen, wurden für 4 Patienten im LightCycler die im Blut zirkulierenden klonalen Rearrangements quantifiziert. Ein Vergleich dieser Daten mit dem klinischen Verlauf ergab bei zwei Patienten eine Tendenz zu einem reziproken Verhältnis, bei einem Patienten im Tumorstadium wurde eine gleichsinnige Entwicklung beider Parameter gesehen. Der Nachweis klonaler Rearrangements in Haut- und Blutproben von SPP-Patienten wäre ein Hinweis auf den Lymphomcharakter dieser Erkrankung. Bei 9 von 14 SPP-Patienten wurde in Blutproben mit Hilfe der für VgammaI-Jgamma1/2 spezifischen Konsensusprimer ein monoklonales Rearrangement ...
Sigma-Aldrich offers abstracts and full-text articles by [R N Daggett, M Kurata, S Abe, I Onishi, K Miura, Y Sawada, T Tanizawa, M Kitagawa].